GLP-1 inhibits its release, further helping to control blood sugar
The FDA-approved dosing for both products includes a gradual dose escalation schedule to minimize gastrointestinal symptoms
Efficacy comparison by clinical trial data The most relevant head-to-head data comes from the SURPASS-2 trial (tirzepatide vs semaglutide 1 mg for type 2 diabetes) and the SURMOUNT-5 trial (tirzepatide vs semaglutide 2.4 mg for obesity)
The bigger questions are whether glucose patterns are stable, whether recent hypoglycemia has occurred, and whether complications could make donation less safe
The study also found that 99.2% of patients achieved at least 5% weight loss, 93.9% lost 10% or more, and nearly half (47.8%) achieved 20% or more body weight loss
Already, the company cant keep up with demand and has had to restrict access to some lower starter doses of the medication so it can meet supply needs for established patients